The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. WARNING: Important safety information is provided in a boxed warning ...

As part of the Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving KRYSTEXXA trial [MIRROR randomized controlled trial (RCT)], baseline estimated glomerular filtration ...

SHENZHEN, CHINA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July ...

Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) ...

TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced topline results met the primary endpoint, showing a significant increase in efficacy using KRYSTEXXA with the ...

A 57-year-old woman with BRAF-positive metastatic melanoma presented to the dermatology clinic for evaluation of rapidly growing nodules on her face and warty growths over her trunk and extremities 3 ...

Methotrexate is a chemotherapeutic agent used as medical therapy for the treatment of ectopic pregnancy. Although it is most commonly administered intramuscularly, obstetricians may inject the ...

Methotrexate 25mg/mL; soln for IV, IM, intra-arterial, or intrathecal administration after dilution; preservative-free. Non-metastatic osteosarcoma in patients who have undergone surgical resection or ...

TOKYO, May 22, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous ...